Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Price Up 5.8% Following Strong Earnings

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)’s share price rose 5.8% on Friday following a better than expected earnings announcement. The company traded as high as $1.74 and last traded at $1.7350. Approximately 1,928,143 shares traded hands during trading, a decline of 35% from the average daily volume of 2,946,142 shares. The stock had previously closed at $1.64.

The biopharmaceutical company reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.03. The firm had revenue of $5.49 million during the quarter, compared to analyst estimates of $3.14 million. Lexicon Pharmaceuticals had a negative return on equity of 40.53% and a negative net margin of 101.08%.

Key Headlines Impacting Lexicon Pharmaceuticals

Here are the key news stories impacting Lexicon Pharmaceuticals this week:

• Positive Sentiment: Q4 results beat expectations — GAAP EPS of -$0.04 vs. -$0.07 consensus and revenue of $5.49M vs. $3.14M expected, which relieved near-term execution concerns and likely helped the stock. Earnings beat summary
• Positive Sentiment: Clinical progress: management confirmed sotagliflozin pivotal milestones are on schedule (including planned NDA resubmission in T1D and enrollment of the SONATA HCM study) and reported a positive End‑of‑Phase‑2 meeting with the FDA for pilavapadin, supporting Phase 3 readiness. These program updates materially de‑risk future value drivers. Press release with clinical updates
• Positive Sentiment: Balance-sheet boost — management disclosed more than $100M in additional cash from a capital raise plus a Novo Nordisk milestone payment, improving runway and reducing near‑term financing risk. Press release with financing detail
• Positive Sentiment: Analyst upgrade / price-target raise — H.C. Wainwright reiterated a Buy rating and raised its target to $6, signaling bullish analyst conviction and providing a large implied upside that can attract momentum buyers. Analyst note / PT raise
• Neutral Sentiment: Management hosted an earnings call and published slides/transcript; these provide more detail for investors but are informational rather than catalytic. Earnings call transcript
• Negative Sentiment: Company remains unprofitable with a negative net margin (~96.8%) and negative return on equity; consensus still forecast a full‑year loss (current consensus ~ -$0.66 EPS), so fundamentals remain challenged absent clinical or commercial validation. Earnings / metrics summary
• Negative Sentiment: Biotech execution and regulatory risk persist — upcoming clinical readouts and the NDA resubmission are binary events that could reverse gains if outcomes disappoint. Clinical & regulatory update

Wall Street Analyst Weigh In

Several analysts have commented on LXRX shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Lexicon Pharmaceuticals in a research note on Thursday, January 22nd. HC Wainwright increased their price target on Lexicon Pharmaceuticals from $4.00 to $6.00 and gave the stock a “buy” rating in a report on Thursday. Finally, Wall Street Zen lowered Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, November 15th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $3.95.

Insider Buying and Selling at Lexicon Pharmaceuticals

In other Lexicon Pharmaceuticals news, Director Invus Global Management, Llc purchased 1,538,462 shares of the company’s stock in a transaction dated Monday, February 2nd. The stock was purchased at an average price of $1.30 per share, with a total value of $2,000,000.60. Following the completion of the purchase, the director owned 1,538,462 shares of the company’s stock, valued at approximately $2,000,000.60. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director Raymond Debbane purchased 100,000 shares of the business’s stock in a transaction that occurred on Monday, February 23rd. The stock was bought at an average cost of $1.47 per share, for a total transaction of $147,000.00. Following the completion of the acquisition, the director directly owned 1,904,186 shares in the company, valued at $2,799,153.42. The trade was a 5.54% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last 90 days, insiders have purchased 1,790,462 shares of company stock valued at $2,369,981. 13.90% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Lexicon Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in LXRX. UBS Group AG grew its stake in shares of Lexicon Pharmaceuticals by 752.1% in the fourth quarter. UBS Group AG now owns 3,007,237 shares of the biopharmaceutical company’s stock worth $3,458,000 after acquiring an additional 2,654,315 shares during the period. CIBC Bancorp USA Inc. bought a new stake in shares of Lexicon Pharmaceuticals during the third quarter valued at approximately $3,240,000. Millennium Management LLC grew its holdings in Lexicon Pharmaceuticals by 133.1% during the 3rd quarter. Millennium Management LLC now owns 3,830,660 shares of the biopharmaceutical company’s stock valued at $5,171,000 after buying an additional 2,187,396 shares in the last quarter. Marshall Wace LLP purchased a new position in Lexicon Pharmaceuticals during the 4th quarter valued at approximately $1,452,000. Finally, AQR Capital Management LLC purchased a new stake in Lexicon Pharmaceuticals during the 1st quarter valued at $541,000. 74.70% of the stock is owned by institutional investors.

Lexicon Pharmaceuticals Stock Up 4.3%

The company has a current ratio of 5.64, a quick ratio of 5.63 and a debt-to-equity ratio of 0.47. The firm has a market cap of $621.53 million, a PE ratio of -12.21 and a beta of 0.94. The business’s 50-day simple moving average is $1.36 and its 200 day simple moving average is $1.33.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company focused on the discovery and development of novel medicines through its proprietary genome biology platform. By leveraging large-scale gene knockout libraries, the company identifies potential therapeutic targets and advances them through preclinical and clinical development. Lexicon’s approach emphasizes the translation of genetic insights into targeted therapies for a range of human diseases.

The company’s most advanced product is telotristat ethyl (sold under the brand name XERMELO), an oral treatment approved for the management of carcinoid syndrome diarrhea in patients inadequately controlled by somatostatin analog therapy.